Biology of Colorectal Cancer in Ulcerative Colitis

Journal of Gastrointestinal Surgery

Volumn 2, Issue 4, 1998, Pages 307-311

  Lashner, Bret A ^a   Shapiro, Bradley D ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; MUCIN; TUMOR MARKER;

ANEUPLOIDY; BIOLOGY; COLON TUMOR; GENETICS; HUMAN; PATHOLOGY; PRECANCER; RECTUM TUMOR; REVIEW; TUMOR SUPPRESSOR GENE; ULCERATIVE COLITIS;

ANEUPLOIDY; BIOLOGY; COLITIS, ULCERATIVE; COLONIC NEOPLASMS; DNA, NEOPLASM; GENES, TUMOR SUPPRESSOR; HUMANS; MUCINS; PRECANCEROUS CONDITIONS; RECTAL NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 0032107327     PISSN: 1091255X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1091-255X(98)80066-8     Document Type: Article

References (65)

1. Bernstein CN, Shanahan F, Weinstein WM. Are we telling patients the truth about surveillance colonoscopy in ulcerative colitis? Lancet 1994;343:71-74.
2. Cohen RD, Hanauer SB. Surveillance colonoscopy in ulcerative colitis: Is the message loud and clear? Am J Gastroenterol 1995;90:2090-2092.
3. Collins RH, Feldman M, Fordtran JS. Colon cancer, dysplasia, and surveillance in patients with ulcerative colitis: A critical review. N Engl J Med 1987;316:1654-1658.
4. Ekbom A, Helmick C, Zack M, et al. Ulcerative colitis and colorectal cancer: A population-based study. N Engl J Med 1990;323:1228-1233.
5. Bernstein CN, Weinstein WM, Levine DS, et al. Physicians' perceptions of dysplasia and approaches to surveillance colonoscopy in ulcerative colitis. Am J Gastroenterol 1995;90:2106-2114.
6. Connell WR, Lennard-Jones JE, Williams CB, et al. Factors affecting the outcome of endoscopic surveillance for cancer in ulcerative colitis. Gastroenterology 1994;107:934-944.
7. Lashner BA. Cancer surveillance in ulcerative colitis: Much ado about little? In Barkin JS, Rogers AI, eds. Difficult Decisions in Digestive Diseases. St. Louis: CV Mosby, 1994.
8. Lynch DAF, Lobo AJ, Sobala GM, et al. Failure of colonoscopic surveillance in ulcerative colitis. Gut 1993;34:1075-1080.
9. Vemulapalli R, Lance P. Cancer surveillance in ulcerative colitis: More of the same or progress? Gastroenterology 1994;107:1196-1199.
10. Morson BC, Pang LSC. Rectal biopsy as an aid to cancer control in ulcerative colitis. Gut 1967;8:423-434.
11. Riddell RH, Goldman H, Ransohoff DF, et al. Dysplasia in inflammatory bowel disease: Standardized classification with provisional clinical applications. Hum Pathol 1983;14:931-968.
12. Lashner BA. Recommendations for colorectal cancer screening in ulcerative colitis: A review of research from a single university-based surveillance program. Am J Gastroenterol 1992;87:168-175.
13. Provenzale D, Kowdley KV, Arora S, et al. Prophylactic colectomy or surveillance for chronic ulcerative colitis? A decision analysis. Gastroenterology 1995;109:1188-1196.
14. Riddell RH. Grading of dysplasia. Eur J Cancer 1995;31A: 1169-1170.
15. Rozen P, Baratz M, Fefer F, et al. Low incidence of significant dysplasia in a successful endoscopic surveillance program of patients with ulcerative colitis. Gastroenterology 1995; 108: 1361-1370.
16. Woolfrich AJ, DaSilva MD, Korelitz BI. Surveillance in the routine management of ulcerative colitis: The predictive value of low-grade dysplasia. Gastroenterology 1992;103:431-438.
17. Melville DM, Jass JR, Morson BC, et al. Observer study of the grading of dysplasia in ulcerative colitis: Comparison with clinical outcome. Hum Pathol 1989;20:1008-1014.
18. Riddell RH. Screening strategies in gastrointestinal cancer. Scand J Gastroenterol 1990;25(Suppl 175):177-184.
19. Rosenstock E, Farmer RG, Petras R, et al. Surveillance for colonic carcinoma in ulcerative colitis. Gastroenterology 1985;89:1342-1346.
20. Meltzer SJ. Dysplasia: Potential and future markers. In Targan SR, Shanahan F, eds. Inflammatory Bowel Disease: From Bench to Bedside. Baltimore: Williams & Wilkins, 1994.
21. Hammarberg C, Rubio C, Slezak P, et al. Flow-cytometric DNA analysis as a means for early detection of malignancy in patients with chronic ulcerative colitis. Gut 1984;25:905-908.
22. Befrits R, Hammarberg C, Rubio C, et al. DNA aneuploidy and histologic dysplasia in long-standing ulcerative colitis: A 10-year follow-up study. Dis Colon Rectum 1994;37:313-320.
23. Hammarberg C, Slezak P, Tribukait B. Early detection of malignancy in ulcerative colitis: A flow-cytometric DNA study. Cancer 1984;53:291-295.
24. Lofberg R, Brostrom O, Karlen P, et al. DNA aneuploidy in ulcerative colitis: Reproducibility, topographic distribution, and relation to dysplasia. Gastroenterology 1992;102:1149-1154.
25. Meling GI, Clausen OPF, Bergan A, et al. Flow cytometric DNA ploidy pattern in dysplastic mucosa and in primary and metastatic carcinomas in patients with longstanding ulcerative colitis. Br J Cancer 1991;64:339-344.
26. Melville DM, Jass JR, Shepherd NA, et al. Dysplasia and deoxyribonucleic acid aneuploidy in the assessment of precancerous changes in chronic ulcerative colitis. Gastroenterology 1988;95:668-675.
27. Fozard JBJ, Quirke P, Dixon MF, et al. DNA aneuploidy in ulcerative colitis. Gut 1986;27:1414-1418.
28. Levine DS, Rabinovitch PS, Haggitt RD, et al. Distribution of aneuploid cell populations in ulcerative colitis with dysplasia or cancer. Gastroenterology 1991;101:1198-1210.
29. Ahnen DJ. Abnormal DNA content as a biomarker of large bowel cancer risk and prognosis. J Cell Biochem Suppl 1992;166:143-150.
30. Boland CR, Montgomery CK, Kim YS. A cancer-associated mucin alteration in benign colonic polyps. Gastroenterology 1982;82:664-672.
31. Boland CR, Montgomery CK, Kim YS. Alterations in human colonic mucin occurring with cellular differentiation and malignant transformation. Proc Natl Acad Sci 1982;79:2051-2055.
32. Clamp JR, Fraser G, Read EA. Study of the carbohydrate content of mucus glycoproteins from normal and diseased colons. Clin Sci 1981;61:229-234.
33. Jass JR, Roberton AM. Colorectal mucin histochemistry in health and disease: A critical review. Pathol Int 1994;44:487-504.
34. Boland CR, Lance P, Levin B, et al. Abnormal goblet cell glycoconjugates in rectal biopsies associated with an increased risk of neoplasia in patients with ulcerative colitis: Early results of a prospective study. Gut 1984;25:1364-1371.
35. Ehsanullah M, Filipe MI, Gazzard B. Mucin secretion in inflammatory bowel disease: Correlation with disease activity and dysplasia. Gut 1982;23:485-489.
36. Fozard JBJ, Dixon MJ, Axon ATR, et al. Lectin and mucin histochemistry as an aid to cancer surveillance in ulcerative colitis. Histopathology 1987;11:385-394.
37. Ahnen DJ, Warren GH, Greene LJ, et al. Search for a specific marker of mucosal dysplasia in chronic ulcerative colitis. Gastroenterology 1987;93:1346-1355.
38. Jass JR, England J, Miller K. Value of mucin histochemistry in follow-up surveillance of patients with long standing ulcerative colitis. J Clin Pathol 1986;39:393-398.
39. Pihl E, Peura A, Hons BS, et al. T-antigen expression by peanut agglutinin staining relates to mucosal dysplasia in ulcerative colitis. Dis Colon Rectum 1985;28:11-17.
40. Itzkowitz SH, Bloom EJ, Kokal WA, et al. Sialosyl-Tn: A novel mucin antigen associated with prognosis in colorectal cancer patients. Cancer 1960;66:1960-1966.
41. Itzkowitz SH, Yuan M, Montgomery CK, et al. Expression of Tn, sialosyl-Tn, and T antigens in human colon cancer. Cancer Res 1989;49:197-204.
42. Itzkowitz S. Carbohydrate changes in colon carcinoma. APMIS 1992;100(Suppl 27):173-180.
43. Itzkowitz SH, Marshall A, Kornbluth A, et al. Sialosyl-Tn antigen: Initial report of a new marker of malignant progression in long-standing ulcerative colitis. Gastroenterology 1995;109:490-497.
44. Orntoft TF, Harving N, Langkilde NC. O-linked mucin-type glycoproteins in normal and malignant colon mucosa: Lack of T-antigen expression and accumulation of Tn and sialosyl-Tn antigens in carcinomas. Int J Cancer 1990;45:666-672.
45. Itzkowitz SH, Young E, Dubois D, et al. Sialosyl-Tn antigen is prevalent and precedes dysplasia in ulcerative colitis: A retrospective case-control study. Gastroenterology 1996;110: 694-704.
46. Carson DA, Lois A. Cancer progression and p53. Lancet 1995;346:1009-1011.
47. Ajioka Y, Watanabe H, Matsuda K. Over-expression of p53 protein in neoplastic changes in ulcerative colitis: Immunohistochemical study. J Gastroenterol 1995;30(Suppl VIII):33-35.
48. Burmer GC, Crispin DA, Kolli VR, et al. Frequent loss of a p53 allele in carcinomas and their precursors in ulcerative colitis. Cancer Commun 1991;3:167-172.
49. Burmer GC, Rabinovitch PS, Haggitt RC, et al. Neoplastic progression in ulcerative colitis: Histology, DNA content, and loss of a p53 allele. Gastroenterology 1992;103:1602-1610.
50. Greenwald BD, Harpaz N, Yin J, et al. Loss of heterozygosity affecting the p53, Rb, and MCC/APC tumor suppressor gene loci in dysplastic and cancerous ulcerative colitis. Cancer Res 1992;52:741-745.
51. Harpaz N, Peck AL, Yin J, et al. p53 protein expression in ulcerative colitis-associated colorectal dysplasia and carcinoma. Hum Pathol 1994;25:1069-1074.
52. Joslyn G, Carlson M, Thliveris A, et al. Identification of deletion mutations and three new genes at the familial polyposis locus. Cell 1991;66:601-613.
53. Powell SM, Zilz N, Beazer-Barclay Y, et al. APC mutations occur early during colorectal tumorigenesis. Nature 1991;359: 235-237.
54. Tarmin L, Yin J, Harpaz N, et al. Adenomatous polyposis coli gene mutations in ulcerative colitis-associated dysplasias and cancers versus sporadic colon neoplasms. Cancer Res 1995;55: 2035-2038.
55. Taylor HW, Boyle M, Smith SC, et al. Expression of p53 in colorectal cancer and dysplasia complicating ulcerative colitis. Br J Surg 1993;80:442-444.
56. Yin J, Harpaz N, Tong Y, et al. p53 point mutations in dysplastic and cancerous ulcerative colitis lesions. Gastroenterology 1993;104:1633-1639.
57. Brentnall TA, Crispin DA, Rabinovitch PS, et al. Mutations in the p53 gene: An early marker of neoplastic progression in ulcerative colitis. Gastroenterology 1994;107:369-378.
58. Baker SJ, Preisinger AC, Jessup JM, et al. p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis. Cancer Res 1990;50:7717-7722.
59. Campo E, Calle-Martin O, Miquel R, et al. Loss of heterozygosity of p53 gene and p53 protein expression in human colorectal carcinomas. Cancer Res 1991;51:4436-4442.
60. Costa A, Marasca R, Valentinis B, et al. p53 gene point mutations in relation to p53 nuclear protein accumulation in colorectal cancers. J Pathol 1995;176:45-53.
61. Kikuchi-Yanoshita R, Konishi M, Ito S, et al. Genetic changes of both p53 alleles associated with the conversion from colorectal adenoma to early carcinoma in familial adenomatous polyposis and non-familial adenomatous polyposis patients. Cancer Res 1992;52:3965-3971.
62. Ilyas M, Talbot IC. p53 expression in ulcerative colitis: A longitudinal study. Gut 1995;37:802-804.
63. Ohue M, Tomita N, Monden T, et al. A frequent alteration of p53 gene in carcinoma in adenoma of colon. Cancer Res 1994;54:4798-4804.
64. Shapiro BD, Goldblum JR, Husain A, Lashner BA. p53 mutations in ulcerative colitis-associated colorectal cancer. Am J Gastroenterol 1996;91:A376.
65. Lashner BA, Hanauer SB, Silverstein MD. Optimal timing of colonoscopy to screen for cancer in ulcerative colitis. Ann Intern Med 1988;108:274-278.